AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox

AI-generated analysis

📈 AbbVie reported Q2 2026 total net revenues of $16.99 billion, representing a 10.2% operational increase year over year.

💊 Skyrizi and Rinvoq combined generated $8.03 billion in revenue for the quarter, significantly outpacing Humira's contribution of $756 million.

📉 Humira revenue fell 36.1% operationally to $756 million following the loss of US exclusivity in 2023.

🛡️ AbbVie settled patent challenges with generic filers, extending US exclusivity for Rinvoq until April 2037.

💰 The company declared a quarterly dividend of $1.73 per share, annualizing to a yield of approximately 2.8% at the reported price.

🤝 AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion in cash to expand its immunology pipeline.

📊 Adjusted diluted EPS rose 22.9% year over year to $3.65, reflecting strong underlying cash economics despite GAAP charges.

🔬 Skyrizi revenue reached approximately $5.5 billion in the quarter, up around 24% operationally from the prior year.

📈 Rinvoq passed $2.5 billion in quarterly revenue, growing 23.7% operationally as it expands into new indications.

🎯 AbbVie raised full-year 2026 revenue guidance by about $300 million to approximately $67.6 billion.

⚖️ The company maintained an adjusted operating margin of 48.3%, absorbing a 1.7 percentage point impact from acquired in-process R&D.

📉 AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.

Bullish Signals
  • Total net revenues grew 10.2% year over year to $16.99 billion in Q2 2026, demonstrating successful portfolio transition.
  • Skyrizi and Rinvoq generated a combined $8.03 billion in revenue for the quarter, comfortably exceeding Humira's peak performance.
  • Adjusted diluted EPS increased 22.9% year over year to $3.65, highlighting strong underlying cash flow generation.
  • The company raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion.
  • AbbVie secured patent settlements extending US exclusivity for Rinvoq until April 2037, providing a decade-long planning horizon.
  • Skyrizi alone reached about $5.5 billion in quarterly revenue, up around 24% operationally from the prior year.
  • AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion to deepen its immunology franchise with a next-generation IL-13 antibody.
  • The company maintains an adjusted operating margin of 48.3%, reflecting the high-margin nature of its branded pharmaceutical business.
  • AbbVie declared a quarterly dividend of $1.73 per share, continuing its track record as a Dividend Aristocrat since inception.
Risk Factors
  • Humira revenue fell 36.1% operationally to $756 million in Q2 2026 following the loss of US exclusivity to biosimilars.
  • AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.
  • The company carries substantial debt originating from the 2020 Allergan acquisition, which competes with buybacks for capital allocation.
Full Analysis
AbbVie (ABBV) reported strong financial performance in the second quarter of 2026, with total net revenues reaching $16.99 billion, a 10.2% increase year over year. This growth was driven primarily by its immunology and neuroscience franchises, specifically Skyrizi and Rinvoq, which generated a combined $8.03 billion in revenue for the quarter. These figures represent a successful transition away from Humira, which contributed only $756 million after losing US exclusivity to biosimilars. The company demonstrated robust profitability with an adjusted gross margin of 84.7% and an adjusted operating margin of 48.3%. AbbVie declared a quarterly dividend of $1.73 per share, maintaining its status as a Dividend Aristocrat while managing substantial debt from the Allergan acquisition. Management also raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion. Strategically, AbbVie agreed to acquire Apogee Therapeutics for an equity value of roughly $10.9 billion to deepen its immunology franchise with a new extended half-life IL-13 antibody. The company also secured patent settlements extending US generic competition for Rinvoq until April 2037 and is pursuing regulatory approvals for new indications in Skyrizi and Rinvoq, including vitiligo and alopecia areata.